Overview
RZLT market data
Price History
RZLT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.07 – $11.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $452.6 · P/B 2.39.
Company News
Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug ProgramBenzinga · Jun 17, 2026, 11:20 AM
Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11Benzinga · Jun 15, 2026, 3:20 PM
Rezolute To Present Four Presentations At Upcoming Annual Meeting Of Endocrine SocietyBenzinga · Jun 4, 2026, 11:40 AM
Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14Benzinga · Jun 3, 2026, 4:45 PM
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On WednesdayBenzinga · Jun 3, 2026, 3:25 PM
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease StudyBenzinga · Jun 2, 2026, 4:31 PM
Rezolute shares are trading higher after the company provided an interim update on its ongoing open-label Phase 3 study of ersodetug in tumor HI. Also, HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $5 price target.Benzinga · Jun 2, 2026, 3:23 PM
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price TargetBenzinga · Jun 2, 2026, 2:23 PM
8-K filing — Rezolute, Inc. (RZLT)SEC EDGAR · Jun 2, 2026, 11:05 AM
Rezolute Reports Mid-Study Results for Rare Hypoglycemia TreatmentBenzinga · Jun 2, 2026, 11:03 AM